Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ossification

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43872   clinical trials with a EudraCT protocol, of which   7291   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Ossification. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-001978-22 Sponsor Protocol Number: I17004 Start Date*: 2019-07-31
    Sponsor Name:CHU de LIMOGES
    Full Title: Injections of Sodium Thiosulfate for ectopic calcifications or ossifications. A pilot study.
    Medical condition: Patient presenting with: - ectopic ossification secondary to iPPSD2 or - ectopic calcification secondary to dermatomyositis or - ectopic calcification secondary to systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10006935 Calcification and ossification, unspecified LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018543-34 Sponsor Protocol Number: 12153599 Start Date*: 2010-06-11
    Sponsor Name:Orthopaedic Syrgery Unit Northern Jytland
    Full Title: NSAIDs INFLUENCE ON HEAL OF COLLES FRACTURE
    Medical condition: Ivestigations hypotheses: 1. NSAIDs provide a significant postoperative pain relief that can make mobilization / rehabilitation faster and easier oedema prophylaxis. 2. NSAIDs do not affect bone he...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009924 Colles' fracture LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000545-22 Sponsor Protocol Number: 2012/462. Start Date*: 2015-08-05
    Sponsor Name:Aarhus University hospital
    Full Title: Effects of Tranexamic Acid on on Intra- and Postoperative bleeding, Blood transfusion and Coagulation in Children Undergoing Craniosynostosis Surgery
    Medical condition: Bleeding during paediatric Craniosynostosis surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10049889 Craniosynostosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001056-35 Sponsor Protocol Number: TXA Start Date*: 2014-11-24
    Sponsor Name:IRCCS Istituto Giannina Gaslini
    Full Title: The Effectiveness and Population Pharmacokinetics and Pharmacogenomics of a Reduced Dose of Tranexamic Acid for Craniosynostosis Surgery: A multicenter study. The TXA Study.
    Medical condition: craniosynostosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10049889 Craniosynostosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002526-36 Sponsor Protocol Number: PVO-1A-204 Start Date*: 2022-07-05
    Sponsor Name:Clementia Pharmaceuticals Inc.
    Full Title: A Phase 2, Open-Label, Efficacy and Safety Study of an RARγ-Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects with Fibrodysplasia Ossificans Progressiva (FOP)
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossificat...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002642-23 Sponsor Protocol Number: NVD-CLN01 Start Date*: 2016-11-28
    Sponsor Name:Novadip Biosciences
    Full Title: A prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by inte...
    Medical condition: Patients diagnosed with symptomatic degenerative spondylolisthesis grade I or II with an indication for spinal fusion of one vertebral segment (L1-S1).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-002496-28 Sponsor Protocol Number: PVO-1A-202 Start Date*: 2015-11-13
    Sponsor Name:Clementia Pharmaceuticals Inc.
    Full Title: A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva ...
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossificat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001453-17 Sponsor Protocol Number: PVO-1A-201 Start Date*: 2015-07-07
    Sponsor Name:Clementia Pharmaceuticals Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia O...
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossificat...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013645-29 Sponsor Protocol Number: 120609 Start Date*: 2009-08-07
    Sponsor Name:Epsom & St Helier's University Hospital NHS Trust
    Full Title: A Two Phase Prospective Randomized Control Trial of Infiltrated Periarticular Multimodal Analgesia following Primary Total Hip Replacement
    Medical condition: Pain relief after total hip replacement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-002516-85 Sponsor Protocol Number: 01-2011 Start Date*: 2011-10-20
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: Open-label study to evaluate the efficacy and tolerability of orally administered rosiglitazone in patients with progressive bone Fibrodysplasia (FOP)
    Medical condition: Fibrodysplasia Ossificans Progressive (FOP) is a rare genetically based disability, characterized by progressive heterotopic ossification, usually associated with congenital malformation of the toes.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028393 Musculoskeletal and connective tissue disorders NEC HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005101-21 Sponsor Protocol Number: GR-OG-279239-01 Start Date*: 2014-12-22
    Sponsor Name:Genera Research Ltd
    Full Title: Safety, tolerability, systemic pharmacokinetics and efficacy of a single dose of Osteogrow (rhBMP6 in autologous Whole Blood Coagulum Derived [WBCD] carrier) delivered locally to the fracture site ...
    Medical condition: Distal radius fracture.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10048049 Wrist fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001691-21 Sponsor Protocol Number: GR-OG-279239-02 Start Date*: 2016-05-17
    Sponsor Name:Genera Research Ltd
    Full Title: SAFETY, TOLERABILITY, rhBMP6 PHARMACOKINETICS AND BONE HEALING EFFECT OF A SINGLE DOSE OF OSTEOGROW (rhBMP6 IN AUTOLOGOUS WHOLE BLOOD COAGULUM DERIVED [WBCD] CARRIER) IN ADULT PATIENTS TREATED BY H...
    Medical condition: Osteoarthritis of the medial knee joint compartment and/or symptomatic varus deformity.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10031300 Osteotomy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002541-29 Sponsor Protocol Number: PVO-1A-301 Start Date*: 2017-12-14
    Sponsor Name:Clementia Pharmaceuticals Inc
    Full Title: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) ES (Ongoing) DE (Completed) FR (Completed) NL (Ongoing) IT (Restarted) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-005035-33 Sponsor Protocol Number: R2477-FOP-1623 Start Date*: 2017-08-15
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progres...
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015383-33 Sponsor Protocol Number: Eto-Dic-01 Start Date*: 2010-08-30
    Sponsor Name:Freistaat Bayern, vertreten durch die Universität Regensburg
    Full Title: Die perioperative Anwendung von Etoricoxib verglichen mit Diclofenac bei Patienten nach Implantation einer Hüftgelenkstotalendoprothese, prospektive, doppelt blinde Phase IIIb Studie
    Medical condition: In this clinical trial we will investigate patients who suffer from primary or secondary coxarthrosis where an implantation of a total hip joint endoprosthesis is indicated. It will be analyzed whe...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048793 Coxarthrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000880-40 Sponsor Protocol Number: R2477-FOP-2175 Start Date*: 2022-08-29
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva
    Medical condition: Fibrodysplasia Ossificans Progressiva
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FI (Ongoing) IT (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003324-20 Sponsor Protocol Number: STOPFOP1 Start Date*: 2020-01-08
    Sponsor Name:VU University Medical Center
    Full Title: Saracatinib trial TO Prevent FOP
    Medical condition: Fibrodyplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004034-11 Sponsor Protocol Number: GR-OG-279239-04 Start Date*: 2022-05-18
    Sponsor Name:Genera Research Ltd
    Full Title: A randomized, evaluator-blinded, dose-ranging, proof of concept study of efficacy, safety and tolerability of Osteogrow-C (rhBMP6 delivered in autologous blood coagulum [ABC] supplemented with sy...
    Medical condition: The treatment of non-union of the tibia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10017088 Fracture nonunion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000431-32 Sponsor Protocol Number: ORTHOUNION Start Date*: 2017-05-25
    Sponsor Name:Universidad Autónoma de Madrid (U.A.M.)
    Full Title: A MULTI-CENTRE, OPEN-LABEL, RANDOMIZED, COMPARATIVE CLINICAL TRIAL OF TWO DIFFERENT DOSES OF BONE MARROW AUTOLOGOUS HUMAN MESENCHYMAL STEM CELLS PLUS BIOMATERIAL VERSUS ILIAC CREST AUTOLOGOUS GRAFT...
    Medical condition: Diaphyseal and/or metaphysodiaphyseal fractures (femur, tibia, humerus) with status of non-union
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10017085 Fracture malunion PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002858-24 Sponsor Protocol Number: D-CA-60130-452 Start Date*: Information not available in EudraCT
    Sponsor Name:Clementia Pharmaceuticals Inc, an Ipsen Company
    Full Title: A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans pr...
    Medical condition: fibrodysplasia ossificans progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) SE (Trial now transitioned) IT (Ongoing) ES (Ongoing) NL (Ongoing) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 06 14:36:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA